Merck Serono, a leading global pharmaceutical company, and Kadimastem, a developer of human pluripotent stem cell-based drug screening and therapeutic solutions, announced today the signing of an MOU aimed at advancing the two companies' current stem cell-based drug screening collaboration which was initiated in April 2012.
http://www.biospace.com/news_story.aspx?StoryID=314204&full=1
http://www.biospace.com/news_story.aspx?StoryID=314204&full=1
No comments:
Post a Comment